$Case report: Pulse cyclophosphamide for treatment of multi-agent-refractory hepatic graft-versus-host disease$

Case report: Pulse cyclophosphamide for treatment of multi-agent-refractory hepatic graft-versus-host disease

Graft-versus-host disease (GVHD) is a common complication in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). GVHD is characterized as either acute or chronic based on symptomatology and histopathological findings. Despite advancements in disease-targeting therapeutics,...

Full description

Bibliographic Details
Main Authors:	Yijun Cai, Amir Ali, Elan Filler, Rua Bayati, Tanjia Toma, Omar Zaki, George Yaghmour, Abdullah Ladha, Karrune Woan, Eric Tam, Preet M. Chaudhary
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-02-01
Series:	Frontiers in Oncology
Subjects:	graft-versus-host disease steroid-refractory hepatic variant allogeneic hematopoietic stem cell transplantation ruxolitinib pulse cyclophosphamide
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1329893/full

Similar Items

Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients
by: Wei C, et al.
Published: (2021-11-01)

Partially replacing cyclophosphamide with bendamustine in combination with cyclosporine A improves survival and reduces xenogeneic graft-versus-host-disease
by: Kristy E. Gilman, et al.
Published: (2023-01-01)

A real life use of ruxolitinib in patients with acute and chronic graft versus host disease refractory to corticosteroid treatment in Latin American patients
by: Mauricio Sarmiento, et al.
Published: (2021-07-01)

PHARMACOECONOMIC ANALYSIS OF DIFFERENT METHODS FOR THE TREATMENT OF STEROID-REFRACTORY GRAFT-VERUS-HOST DISEASE: SINGLE-CENTER STUDY
by: I. S. Moiseev, et al.
Published: (2018-03-01)

Comparison of Post-transplant Cyclophosphamide Containing Immunosuppressive Regimen with Standard Immunosuppressive Regimen in Allogeneic Stem Cell Transplantation from Matched Sibling Donor
by: Osman KARA, et al.
Published: (2021-12-01)

Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
by: Halvard Bonig, et al.
Published: (2023-11-01)

Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease
by: Dong Wang, et al.
Published: (2021-06-01)

More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses?
by: Moisés Manuel Gallardo-Pérez, et al.
Published: (2024-12-01)

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis
by: Shuang Fan, et al.
Published: (2022-08-01)

Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease
by: Abedin S, et al.
Published: (2020-11-01)

Applicability and validation of different prognostic scores in allogeneic hematopoietic cell transplant (HCT) in the post-transplant cyclophosphamide era
by: María Queralt Salas, et al.
Published: (2024-12-01)

Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding
by: Natalia S. Nunes, et al.
Published: (2019-11-01)

Immune Reconstitution of Patients Who Recovered From Steroid-Refractory Acute Graft-Versus-Host Disease After Basiliximab Treatment
by: Dao-Xing Deng, et al.
Published: (2022-07-01)

PT-Cy combined with ruxolitinib and tocilizumab prevents aGVHD after haploidentical HSCT
by: BAI Haocheng, et al.
Published: (2020-09-01)

Haploidentical Hematopoietic Stem Cell Transplantation Followed by ‘Post-Cyclophosphamide’: The Future of Allogeneic Stem Cell Transplant
by: Samuel Cytryn, et al.
Published: (2020-04-01)

Can doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts be reduced?
by: Juan Carlos Olivares-Gazca, et al.
Published: (2023-12-01)

The effectiveness of ruxolitinib and cyclophosphamide combination on T helper 17 and regulatory T cells in rat experimental membranous glomerulonephritis
by: Rahim Iranzad, et al.
Published: (2024-08-01)

Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
by: Mauricio Sarmiento Maldonado, et al.
Published: (2017-12-01)

Treatment Response in Individual Organs Affected by Chronic Graft-Versus-Host Disease
by: Takanobu Morishita, et al.
Published: (2025-02-01)

Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation
by: Yanmin Zhao, et al.
Published: (2021-06-01)

Post-transplant cyclophosphamide versus anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation from unrelated donors: A systematic review and meta-analysis
by: Lu Tang, et al.
Published: (2023-02-01)

Anti-PD-1 combined with hypomethylating agent and CAG regimen bridging to allogeneic hematopoietic stem cell transplantation: a novel strategy for relapsed/refractory acute myeloid leukemia
by: Yu-Xin Wang, et al.
Published: (2024-08-01)

Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation
by: Hirohisa Nakamae
Published: (2024-06-01)

Treatment of steroid-refractory graft versus host disease in children
by: Francesca Gottardi, et al.
Published: (2023-09-01)

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
by: Yin Liu, et al.
Published: (2022-11-01)

Cyclophosphamide-Induced Tolerance in Allogeneic Transplantation: From Basic Studies to Clinical Application
by: Koji Kato, et al.
Published: (2020-01-01)

Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review
by: Polina Bellman, et al.
Published: (2024-04-01)

The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study
by: Yang W, et al.
Published: (2021-02-01)

COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR
by: Selim SAYIN
Published: (2024-02-01)

Evaluation of Reversed Administration Order of Busulfan (BU) and Cyclophosphamide (CY) as Conditioning on Liver Toxicity in Allogenic Hematopoietic Stem Cell Transplantation (ALL-HSCT)
by: Mani Ramzi, et al.
Published: (2020-07-01)

Current status of conditioning regimens in haploidentical hematopoietic cell transplantation
by: Junichi Sugita, et al.
Published: (2024-12-01)

Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials
by: Chengxin Luo, et al.
Published: (2023-06-01)

Long-term survival in a patient with primary refractory AML after salvage allogeneic hematopoietic transplantation and post-transplant localized irradiation and venetoclax maintenance: a case report
by: Yili Fan, et al.
Published: (2023-12-01)

Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease
by: Pamela Paplham, et al.
Published: (2014-01-01)

Comparison of oral and intravenous cyclophosphamide in children with steroid-resistant nephrotic syndrome
by: Eka Laksmi Hidayati, et al.
Published: (2011-10-01)

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
by: Enrico Maffini, et al.
Published: (2016-08-01)

Decreasing the steroid rapidly may help to improve the clinical outcomes of patients with intestinal steroid-refractory acute graft-versus-host disease receiving basiliximab treatment
by: Cong Cheng, et al.
Published: (2024-03-01)

Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxis
by: Diana T. Samuels, et al.
Published: (2025-02-01)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
by: Nikolas von Bubnoff, et al.
Published: (2018-11-01)

Autoimmune Limbic Encephalitis in Patients with Hematologic Malignancies after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide
by: Bu Yeon Heo, et al.
Published: (2023-08-01)